ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RENX Renalytix Plc

33.50
-1.50 (-4.29%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50 -4.29% 33.50 32.00 35.00 35.00 33.50 35.00 92,711 16:26:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Services, Nec 3.4M -46.22M -0.4626 -0.72 33.48M
Renalytix Plc is listed in the Services sector of the London Stock Exchange with ticker RENX. The last closing price for Renalytix was 35p. Over the last year, Renalytix shares have traded in a share price range of 10.25p to 145.00p.

Renalytix currently has 99,930,156 shares in issue. The market capitalisation of Renalytix is £33.48 million. Renalytix has a price to earnings ratio (PE ratio) of -0.72.

Renalytix Share Discussion Threads

Showing 1001 to 1024 of 2800 messages
Chat Pages: Latest  52  51  50  49  48  47  46  45  44  43  42  41  Older
DateSubjectAuthorDiscuss
14/1/2021
08:16
Bought some first thing too, bonkers price action
donald pond
14/1/2021
08:14
If they execute to plan we could easily see a mkt cap of 10bn usd+ in 3-5 years.

Still in the foothills here but the US at least seems to be waking up.

mr roper
14/1/2021
08:12
Yep grabbed some more!
lottsgold
14/1/2021
08:11
It should be music to investors ears, when the CEO can effectively and clearly state not only the 'initial' very large target market, but importantly why there are no direct competitors and effectively communicate and demonstrate the 'very high' barriers to entry.
wan
14/1/2021
04:39
Renalytix finished up over 18% at $20.50 on Nasdaq. I make that equivalent to £8.25 per share.


During the presentation Co-founder and CEO James McCullough also referred to Kantaro's antibody test as important testing technology and that they are making great strides to get this test out (EKF also gets mentioned in this regard). He states that quantitative antibody testing will be a significant issue in 2021 and 'beyond'.

The following article adds more colour and some transparency regarding the FDA approval, which looks set to change, but EKF can already distribute in Europe on the basis of a fully quantitative test -

Next-gen antibody tests promise more answers to Covid-19 questions

The new tests can open a window into the duration of immunity and to the antibody levels needed to sustain it. But first, a universal standard is needed to ensure results are comparable between tests.
By JOEL BERG
11th January 2021

“There’s still a lot to be learned,” said Michael Haydock, a senior director at Informa Pharma Intelligence in London.

For example, he said, researchers don’t know if there is a threshold number of antibodies a person needs to maintain immunity, Haydock said. Quantitative tests could help pinpoint a threshold and track whether antibodies fall below it, potentially necessitating a booster vaccine.

“Measuring that is going to be very important,” Haydock said in a phone interview. Tests also may be able to quantify differences in immune response based on age, race and other factors.

In addition, quantitative tests can be used to assess people who have recovered from Covid-19 and want to donate plasma for use in convalescent plasma therapy, a treatment for the virus. Researchers also may be interested in understanding the response to Covid-19 vaccines among those who are already on therapies that modify their immune systems.

“That’s the nature of this pandemic, that you’re trying to move forward when you have more questions than you have answers. Antibody testing can help answer those questions,” said Sara Barrington, chief commercial officer for Kantaro Biosciences.

The New York-based company offers a quantitative antibody test for Covid-19 using technology developed at Mount Sinai Health System early in the pandemic. Kantaro is a joint venture between Mount Sinai and RenalytixAI, a diagnostics company based in the United Kingdom.

Complicating the issue is the lack of an agreed-upon standard for measuring antibodies. However, clarity is on the horizon.

The World Health Organization is expected to set standards soon, Barrington said in a phone interview.

“With an international standard, you’d be able to compare the results across different tests,” said Erik Lium, Kantaro’s chairman and the chief commercial innovation officer at Mount Sinai.

In November, the Food and Drug Administration approved Kantaro’s test for emergency use. But the approval comes with a qualification: the test, called COVID-SeroKlir, is considered semi-quantitative.

The FDA appears to be waiting for the international standard to be set before declaring tests fully quantitative, Barrington said. However, European regulators are not waiting. They cleared COVID-SeroKlir for use as a fully quantitative test.

Full story -

wan
13/1/2021
21:26
The presentation was exceptional and the q and a very interesting. Good to see the US market leading the way.
mr roper
13/1/2021
21:23
Huge volume in US, equivalent of 700,000 shares today compared to 87,000 in UK
donald pond
13/1/2021
21:06
£7.50p equivalence to Nasdaq price.
busterdog2
13/1/2021
19:52
Only have a small stake here but looking like we've caught the eye of the NASDAQ bunch. Long may it continue!
lottsgold
13/1/2021
19:37
THrough $22 now. +27%
mr roper
13/1/2021
19:26
$rnlx absolutely flying on Nasdaq. Broke the 20 buck barrier and now up 18%. Hoping for similar here tomorrow. A break and run at 800p would be great.
mr roper
13/1/2021
16:54
$rnlx at$19.50 I make that approx 720p
mr roper
13/1/2021
16:25
Breaking out Stateside. When the CEO equates MCIT as being in at the start of the gold rush you can’t help but think a lot of folk have not cottoned on to the opportunity here. Absolutely huge.
mr roper
13/1/2021
15:55
I concur, very encouraging indeed, and that's to say the least!
wan
13/1/2021
15:45
Exceptional presentation.
mr roper
13/1/2021
07:55
Good news thx
nw99
13/1/2021
07:41
Today's news demonstrates that the ground has been laid and the runway is clear subject to FDA approval. I have confidence for approval being attained this year due to Renalytix early engagement with FDA which has already resulted in KindneyIntelx being granted FDA breakthrough designation back in May 2019.

I will be tuning into today's presentation.

wan
12/1/2021
22:20
Good work from Stifel. Nicely timed for the day before the conference. Should get Renx some additional attention.
mr roper
12/1/2021
20:54
Up 10% now, which is nice
mad foetus
12/1/2021
20:09
From Seeking Alpha


RNLX : Exact and Exact Sciences trade higher; Seen as beneficiaries from new CMS rule • 2:43 PM

Finalization to the Medicare Coverage of Innovative Technology (“MCIT”) rule from CMS will benefit Renalytix (RNLX +3.9%), Exact Sciences (EXAS +3.7%), and Bio-Techne Corporation (TECH -0.6%), says Stifel in an industry update.
Proposed in August, the new rule expects to cover devices with FDA breakthrough designation on the date of their respective market authorization leading to a four-year coverage thereafter.
These devices have typically received Medicare coverage via National Coverage Decisions (“NCD”) or Local Coverage Decisions (“LCD”), a process that could take a year to finalize.
While waiting for more details with the final ruling, the analysts attempt to identify the significant beneficiaries.
With the breakthrough status, Renalytix’s KidneyIntelX platform is awaiting FDA approval. Exact's liver test and EPI test from Bio-Techne (NASDAQ:TECH) have breakthrough status and yet to file for FDA approval.

peterc1970
11/1/2021
08:14
My post from the Verici thread -

Very important news today.

This is an exciting development because invasive tissue biopsies remain the primary method of diagnosing fibrotic diseases. Thus, the ability to measure disease specific biomarkers non-invasively is highly desired. This potentially (at this stage) puts Verici firmly in Care DX's space (a large player) and potentially of great interest to the likes of Davita! It is a very large market that's unfortunately set to get much bigger, but importantly it's set get a lot more attention in terms of enabling transplants.

wan
06/1/2021
11:20
Thanks for the heads-up Faz
wan
06/1/2021
10:52
This announcement today shows just how much AZN - a RENX partner- is involved in treating chronic kidney disease.
faz
05/1/2021
15:54
$rnlx just hit an ATH on the Nasdaq, hoping we follow suit here shortly...
mr roper
Chat Pages: Latest  52  51  50  49  48  47  46  45  44  43  42  41  Older

Your Recent History

Delayed Upgrade Clock